A critical review of akathisia, and its possible association with suicidal behaviour

Human Psychopharmacology

Volumn 16, Issue 7, 2001, Pages 495-505

  Hansen, Lars ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Akathisia; Antidepressants; Antipsychotics; Suicide

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ATENOLOL; BENZATROPINE; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIPERIDEN; BUTYROPHENONE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CLOZAPINE; CYPROHEPTADINE; DIAZEPAM; FLUOXETINE; HALOPERIDOL; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE; PLACEBO; PROCYCLIDINE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID;

AKATHISIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; DRUG POTENTIATION; EMOTIONAL STRESS; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; MULTICENTER STUDY; PATHOPHYSIOLOGY; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOPHRENIA; SUICIDAL BEHAVIOR; SUICIDE; SUICIDE ATTEMPT; TARDIVE DYSKINESIA; THINKING;

EID: 0034748456     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.325     Document Type: Review

References (75)

1. Adjunctive fluoxetine in haloperidol established schizophrenics
2. Polypharmacy akathisia and associated suicide attempts
3. Treatment of neuroleptic-induced akathisia with nicotine patches
4. Extrapyramidal symptoms with selective serotonin reuptake inhibitors
5. Multiple fixed doses of 'Seroquel' (Quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
6. A survey of drug induced extrapyramidal reactions
7. Akathisia-induced suicidal behaviour
8. Addition of fluoxetine to treatment of schizophrenic patients
9. Pharmacological provocation and prevention of suicidal behaviour
10. Barnes Akathisia Rating Scale
11. Beta 2-receptor density on mononuclear blood cells in patients suffering from neuroleptic-induced akathisia
12. Audit: Prescription of 'as required' (p.r.n.) medication in an in-patient setting
13. Dopamine and depression
14. Poor response to fluoxetine: Underlying depression, serotonergic overstimulation or a therapeutic window?
15. Motor and mental aspects of acute extrapyramidal syndromes
16. Effects of clozepine therapy in schizophrenic individuals at risk for tardive dyskinesia
17. Suicide attempt due to metoclopramide-induced akathisia
18. Drug-induced akathisia revisited
19. Assessment of EPS and tardive dyskinesia in clinical trials
20. Long-term safety and efficacy of amisulpride in subchronic and chronic schizophrenia
21. Akathisia and violence
22. Saving Lives: Our Healthier Nation
23. Comparison of propanolol, sotolol and betaxolol in the treatment of neuroleptic-induced akathisia
24. Nefrazodone and akathisia
25. The pharmacological treatment of neuroleptic induced akathisia
26. The effect of activation procedures on neuroleptic induced akathisia
27. Sodium valproate and biperiden in neuroleptic induced akathisia, parkinsonism and hyperkinesia: A double blind cross over study with placebo
28. The prevalence of metoclopramide-induced acute extrapyramidal movement disorders
29. Selective serotonin-reuptake inhibitor-induced movement disorders
30. Akathisia, suicidality and fluoxetine
31. Drug induced akathisia, suicidal ideation and its treatment in the elderly
32. L'akathisie
33. Immediate effects of droperidol
34. The fluoxetine and suicide controversy: A review of the evidence
35. Management of acute extrapyramidal effects induced by antipsychotic drugs
36. Low serum iron in patients with neuroleptic-induced akathisia and dystonia under antipsychotic drug treatment
37. Dilatiazem and akathisia
38. Severe akathisia during olanzapine treatment of acute schizophrenia
39. Antipsychotic drug-induced dysphoria
40. SSRI-induced extrapyramidal side-effects and akathisia: Implications for treatment
41. Propanolol in the treatment of neuroleptic-induced akathisia
42. Fluoxetine induced akathisia
43. The pathophysiology of extra-pyramidal side effects of neuroleptic drugs
44. Risk factors for the development of neuroleptic induced akathisia
45. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics
46. Antidepressants and suicidal risk
47. Sertraline and akathisia: Spontaneous resolution
48. Polypharmacy akathisia and associated suicide attempts
49. Suicide in psychiatric hospital in-patients. Risk factors and their predictive power
50. Reexposure to fluoxetine after serious suicide attempts by three patients: The role of akathisia
51. Drug-induced akathisia: Subjective experience and objective findings
52. Research diagnostic criteria for drug-induced akathisia
53. The epidemiology of drug-induced akathisia. Chronic, tardive, and withdrawal akathisias
54. Pharmacological characterization of tardive akathisia
55. Acute drug-induced akathisia is not associated with low serum iron status
56. The present status of akathisia
57. The effects of beta-adrenoceptor antagonists on a rat model of neuroleptic-induced akathisia
58. Effects of specific dopamine D1 and D2 receptor antagonists and agonists and neuroleptic drugs on emotional defecation in a rat model of akathisia
59. Homicide and suicide associated with akathisia and haloperidol
60. Akathisia and sertraline
61. A case of suicidal and homicidal ideation and akathisia in a double crossover study
62. Le traitement de la maladie de Parkinson et des manifestations extrapyramidales par le diehylaminoethyl N-thiodiphenylamine (2987RP): Resultats d'une annee d'application
63. Case report: Akathisia abolished by passive movement
64. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients
65. Relationship between the locomotor hyperactivity induced by A10 lesions and the destruction of the frontocortical dopaminergic innovation in the rat
66. Serotonergic modulation of striate D2 dopamine receptor binding in humans measured with positron emission tomography
67. Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression
68. Akathisia with haloperidol and thiothixene
69. Neuropsychiatric effects of antimalarias
70. Clozapine
71. Opioid responsiveness in patients with neuroleptic-induced akathisia